Close
ACHEMA MIDDLE EAST 2026
5th LNP Formulation & Process Development Summit

Press Statements

      U.S. FDA Approves Expanded Indication for Truvada for Reducing the Risk of Acquiring HIV-1 in Adolescents

      FDA Approvals
      Gilead Sciences, Inc. announced that the U.S. FDA has approved once-daily oral Truvada® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)—in combination with safer sex...

      Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical...

      Clinical Trials
      Teva Pharmaceutical Industries Ltd. announced the publication of data from the Phase III HALO study evaluating the efficacy, safety, and tolerability of both quarterly...

      CIMZIA is The First Therapy to Demonstrate Positive Results in a 52-week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study

      Clinical Trials
      UCB announced positive topline results from C-AXSPAND, a Phase 3 placebo controlled study to investigate the efficacy of CIMZIA® (certolizumab pegol) on the signs...

      Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies

      Drug Development
      Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and Daiichi Sankyo Company, Limited announced that they entered into a new license agreement,...

      Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care

      Clinical Trials
      Eli Lilly and Company announced that new results from a number of studies across the company's oncology product and pipeline portfolio will be presented...

      Lilly’s Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache

      Clinical Trials
      Eli Lilly and Company announced that galcanezumab met its primary endpoint in a Phase 3 study of patients with episodic cluster headache, demonstrating statistically...

      CORRECTING and REPLACING Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the JAMA

      Clinical Trials
      Teva Pharmaceutical Industries Ltd. announced the publication of data from the Phase III HALO study evaluating the efficacy, safety, and tolerability of both quarterly...

      Subscribe Our Newsletter

      White Papers

      The Future of Digital Health

      Whitepapers 0
      The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

      Five Best Practices to Deliver Exceptional Multichannel Experiences

      Whitepapers 0
      A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

      The Impact and Use of Social Media in Pharmacovigilance

      Whitepapers 0
      Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...

      About us

      Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and
      comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector. . . Read More

      Resources

      Advertise

      Subscribe

      Copyright © Value Media Group 2026. All rights reserved.